161 related articles for article (PubMed ID: 18072945)
1. Post-translational modification and proteolytic processing of urinary osteopontin.
Christensen B; Petersen TE; Sørensen ES
Biochem J; 2008 Apr; 411(1):53-61. PubMed ID: 18072945
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive identification of post-translational modifications of rat bone osteopontin by mass spectrometry.
Keykhosravani M; Doherty-Kirby A; Zhang C; Brewer D; Goldberg HA; Hunter GK; Lajoie G
Biochemistry; 2005 May; 44(18):6990-7003. PubMed ID: 15865444
[TBL] [Abstract][Full Text] [Related]
3. Characterization of anti-osteopontin monoclonal antibodies: Binding sensitivity to post-translational modifications.
Kazanecki CC; Kowalski AJ; Ding T; Rittling SR; Denhardt DT
J Cell Biochem; 2007 Nov; 102(4):925-35. PubMed ID: 17786932
[TBL] [Abstract][Full Text] [Related]
4. Posttranslational modifications of bovine osteopontin: identification of twenty-eight phosphorylation and three O-glycosylation sites.
Sørensen ES; Højrup P; Petersen TE
Protein Sci; 1995 Oct; 4(10):2040-9. PubMed ID: 8535240
[TBL] [Abstract][Full Text] [Related]
5. Post-translationally modified residues of native human osteopontin are located in clusters: identification of 36 phosphorylation and five O-glycosylation sites and their biological implications.
Christensen B; Nielsen MS; Haselmann KF; Petersen TE; Sørensen ES
Biochem J; 2005 Aug; 390(Pt 1):285-92. PubMed ID: 15869464
[TBL] [Abstract][Full Text] [Related]
6. Chromogranin A from bovine adrenal medulla: molecular characterization of glycosylations, phosphorylations, and sequence heterogeneities by mass spectrometry.
Bauer SH; Zhang XY; Van Dongen W; Claeys M; Przybylski M
Anal Biochem; 1999 Oct; 274(1):69-80. PubMed ID: 10527498
[TBL] [Abstract][Full Text] [Related]
7. Kinetics of calcium oxalate crystal growth in the presence of osteopontin isoforms: an analysis by scanning confocal interference microcopy.
Langdon A; Wignall GR; Rogers K; Sørensen ES; Denstedt J; Grohe B; Goldberg HA; Hunter GK
Calcif Tissue Int; 2009 Mar; 84(3):240-8. PubMed ID: 19189038
[TBL] [Abstract][Full Text] [Related]
8. Proteomic analysis and immunodetection of the bovine milk osteopontin isoforms.
Bissonnette N; Dudemaine PL; Thibault C; Robitaille G
J Dairy Sci; 2012 Feb; 95(2):567-79. PubMed ID: 22281321
[TBL] [Abstract][Full Text] [Related]
9. Site-specific structural characterization of O-glycosylation and identification of phosphorylation sites of recombinant osteopontin.
Li H; Shen H; Yan G; Zhang Y; Liu M; Fang P; Yu H; Yang P
Biochim Biophys Acta; 2015 Jun; 1854(6):581-91. PubMed ID: 25450502
[TBL] [Abstract][Full Text] [Related]
10. Cell type-specific post-translational modifications of mouse osteopontin are associated with different adhesive properties.
Christensen B; Kazanecki CC; Petersen TE; Rittling SR; Denhardt DT; Sørensen ES
J Biol Chem; 2007 Jul; 282(27):19463-72. PubMed ID: 17500062
[TBL] [Abstract][Full Text] [Related]
11. Phosphorylation of osteopontin peptides mediates adsorption to and incorporation into calcium oxalate crystals.
O'Young J; Chirico S; Al Tarhuni N; Grohe B; Karttunen M; Goldberg HA; Hunter GK
Cells Tissues Organs; 2009; 189(1-4):51-5. PubMed ID: 18728346
[TBL] [Abstract][Full Text] [Related]
12. Osteopontin is highly susceptible to cleavage in bovine milk and the proteolytic fragments bind the αVβ₃-integrin receptor.
Christensen B; Sørensen ES
J Dairy Sci; 2014; 97(1):136-46. PubMed ID: 24268404
[TBL] [Abstract][Full Text] [Related]
13. Osteopontin is cleaved at multiple sites close to its integrin-binding motifs in milk and is a novel substrate for plasmin and cathepsin D.
Christensen B; Schack L; Kläning E; Sørensen ES
J Biol Chem; 2010 Mar; 285(11):7929-37. PubMed ID: 20071328
[TBL] [Abstract][Full Text] [Related]
14. Nucleocytoplasmic glycosylation, O-GlcNAc: identification and site mapping.
Zachara NE; Cheung WD; Hart GW
Methods Mol Biol; 2004; 284():175-94. PubMed ID: 15173616
[TBL] [Abstract][Full Text] [Related]
15. Role of phosphate groups in inhibition of calcium oxalate crystal growth by osteopontin.
Hunter GK; Grohe B; Jeffrey S; O'Young J; Sørensen ES; Goldberg HA
Cells Tissues Organs; 2009; 189(1-4):44-50. PubMed ID: 18703867
[TBL] [Abstract][Full Text] [Related]
16. Urinary concentration of osteopontin and association with urinary supersaturation and crystal formation.
Tsuji H; Tohru U; Hirotsugu U; Masanori I; Yuji H; Takashi K
Int J Urol; 2007 Jul; 14(7):630-4. PubMed ID: 17645608
[TBL] [Abstract][Full Text] [Related]
17. Control of calcium oxalate crystal growth by face-specific adsorption of an osteopontin phosphopeptide.
Grohe B; O'Young J; Ionescu DA; Lajoie G; Rogers KA; Karttunen M; Goldberg HA; Hunter GK
J Am Chem Soc; 2007 Dec; 129(48):14946-51. PubMed ID: 17994739
[TBL] [Abstract][Full Text] [Related]
18. Post-translational modifications of human thrombin-activatable fibrinolysis inhibitor (TAFI): evidence for a large shift in the isoelectric point and reduced solubility upon activation.
Valnickova Z; Christensen T; Skottrup P; Thøgersen IB; Højrup P; Enghild JJ
Biochemistry; 2006 Feb; 45(5):1525-35. PubMed ID: 16445295
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of hydroxyapatite formation by osteopontin phosphopeptides.
Pampena DA; Robertson KA; Litvinova O; Lajoie G; Goldberg HA; Hunter GK
Biochem J; 2004 Mar; 378(Pt 3):1083-7. PubMed ID: 14678013
[TBL] [Abstract][Full Text] [Related]
20. MAPRes: Mining association patterns among preferred amino acid residues in the vicinity of amino acids targeted for post-translational modifications.
Ahmad I; Qazi WM; Khurshid A; Ahmad M; Hoessli DC; Khawaja I; Choudhary MI; Shakoori AR;
Proteomics; 2008 May; 8(10):1954-8. PubMed ID: 18491291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
